• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds

    Simply Wall St·08/13/2026 13:26:52
    語音播報
    • In early August 2026, ResMed Inc. reported higher fourth-quarter and full-year sales and earnings, lifted its quarterly dividend to US$0.66 per share, and confirmed completion of a US$1.40 billion buyback program that has retired about 7.92% of its shares since 2014.
    • At the same time, management flagged a softer outlook tied to suspended ventilator sales after an FDA Class 1 recall, putting more emphasis on how resilient its broader sleep-health and digital platforms can be in supporting future performance.
    • Now we’ll explore how the 10% dividend increase interacts with a softer ventilator outlook to reshape ResMed’s longer-term investment narrative.

    AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    ResMed Investment Narrative Recap

    To own ResMed, you need to believe its core sleep therapy and digital health businesses can offset pressure in ventilators, reimbursement and competition. The recent Class 1 recall and suspended ventilator sales highlight regulatory and product risk as the key near term overhang, while the main short term catalyst is whether the broader sleep and software portfolio can keep earnings and cash flow on a stable footing. The August results and guidance do not fundamentally change that equation.

    Among the latest announcements, the 10% dividend increase to US$0.66 per share stands out. It sits alongside solid full year earnings and the completion of a US$1.40 billion buyback that retired about 7.92% of shares since 2014, reinforcing how much of ResMed’s investor appeal still rests on recurring cash generation from sleep therapy and digital platforms, rather than on ventilator volumes alone.

    Yet behind the higher dividend, investors should be aware that the FDA Class 1 recall and suspended ventilator sales could...

    Read the full narrative on ResMed (it's free!)

    ResMed's narrative projects $6.5 billion revenue and $1.8 billion earnings by 2029. This requires 5.4% yearly revenue growth and about a $0.3 billion earnings increase from $1.5 billion today.

    Uncover how ResMed's forecasts yield a $247.93 fair value, a 10% upside to its current price.

    Exploring Other Perspectives

    RMD 1-Year Stock Price Chart
    RMD 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming earnings could reach about US$1.8 billion by 2029, which is a far brighter path than the recall related risks around ventilators and reimbursement that we are now seeing, so it is worth asking whether those assumptions still hold up.

    Explore 6 other fair value estimates on ResMed - why the stock might be worth as much as 43% more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.

    Interested In Other Possibilities?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.